Company Profiles | Fabric Genomics

Leadership Profiles

Martin Reese, Ph.D. headshot
TeamModalOverlay

Martin Reese, Ph.D.

Co-Founder, President, and CEO

Dr. Reese is an internationally recognized expert and entrepreneur in Genomics and Bioinformatics. Prior to founding Fabric Genomics, Martin served as Vice President of Discovery Informatics for ValiGen, and co-founded Neomorphic, where he served as President and Chief Scientific Officer. The human genome annotation software that Martin developed at Neomorphic, provided the foundation for the successful commercialization of microarrays by Affymetrix. During his career he has been actively involved in community-wide assessments of genome annotation. He organized the state-of-the-art Genome Annotation Assessment Project and was a member of the Berkeley Drosophila Genome Project, which provided the essential proof-of-concept platform for “shotgun” sequencing technology. At the Lawrence Berkeley National Laboratories Martin developed gene-finding algorithms for the Human Genome Project. He holds a Masters degree in Medical Informatics from the University of Heidelberg and a Ph.D. in Genetics jointly from the University of Hohenheim, Germany and the University of California, Berkeley.

John Stuelpnagel, D.V.M headshot
TeamModalOverlay

John Stuelpnagel, D.V.M.

Co-Founder, Chairman of the Board of Directors

Dr. Stuelpnagel currently serves as the Executive Chairman of Ariosa Diagnostic since 2009 and a board member at Sequenta, two leading genomic-based Diagnostic companies in the San Francisco bay area. Prior to this, John co-founded Illumina Inc., a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and biological function.


John was involved in making Illumina one of the most successful life science companies, serving as its first President and Chief Executive Officer from 1998 to 1999, Vice President of Business Development from 1999 to 2002, Senior Vice President of Operations from 2002 to 2005 and Chief Operating Officer from January 2005 to April 2008.


Prior, he was a venture capitalist at CW Group from 1997 to 1998 and with Catalyst Partners, a venture capital firm, from 1996 to 1997. While at CW Group, John uncovered what would become Illumina’s BeadArray technology at Tufts University and negotiated an exclusive license to that technology which led to the founding of Illumina Inc. He also served as a member of the Board of Directors of Illumina Inc. from April 1998 until April 2008. John received his B.S. in Biochemistry and his Doctorate in Veterinary Medicine from the University of California, Davis and his M.B.A. from the University of California, Los Angeles.

Paul Billings headshot
TeamModalOverlay

Paul Billings, M.D., Ph.D.

Co-Founder and Acting Chief Medical Officer

Dr. Billings serves as Chief Medical Officer at Fabric Genomics. Prior to joining Fabric Genomics, Dr. Billings was CMO at Life Technologies, acquired by Thermo Fisher Scientific, Inc. (NYSE: TMO). Before that he was founding and acting Director and Chief Scientific Officer of the Genomic Medicine Institute at El Camino Hospital. Dr. Billings served as President, CEO and Director of CELLective Dx Corporation. Dr. Billings currently serves on the Scientific Advisory Board of the FDA, the Genomic Medicine Advisory Committee at the Dept. of Veterans Affairs, and the National Academy of Sciences Institute of Medicine’s Roundtable on Genomics. He was Deputy Chief of Staff and Chief of General Medicine at the Palo Alto VA Healthcare System and Stanford Medical School, and then CMO and Deputy Network Director of VISN 17 in the Department of Veterans Affairs. He has been Professor of Anthropology (adjunct) at UC Berkeley and has published extensively on topics in immunology, genetics and medicine. Dr. Billings received an A.B. summa cum laude from UC San Diego, and both his M.D. and Ph.D. degrees from Harvard University.

Charlene Son Rigby headshot
TeamModalOverlay

Charlene Son Rigby

Chief Business Officer

Charlene is responsible for customer success, business development and regulatory at Fabric Genomics. Charlene has spent her career building businesses at the intersection of data, technology and life sciences. Previous to Fabric Genomics, she was responsible for all go-to-market activities at Metamarkets, a big data analytics startup. Prior to Metamarkets, Charlene was Vice President of Business Planning at Oracle where she rolled out Analytics for the sales organization, and Executive Director of Sales Operations at Siebel Systems, a $2B license business. She also led product management at DoubleTwist, a bioinformatics startup. Charlene started her career as a neuroscience researcher at Syntex (acquired by Roche). She holds a B.A. in Human Biology from Stanford University and an M.B.A. from the Haas School of Business at U.C. Berkeley.

Michael Vishnevetsky, PhD
TeamModalOverlay

Michael Vishnevetsky, Ph.D.

Vice President of Business Development

Dr. Vishnevetsky serves as Vice President of Business Development at Fabric Genomics with focus on corporate partnerships and strategic alliances. Prior to joining Fabric Genomics Michael focused on Pharma engagement and companion diagnostics (CDx) test development, serving subsequently as a Head of Global Business Development at Personal Genome Diagnostics and Invivoscribe. Prior to that, Dr. Vishnevetsky held business development positions at Pacific Biosciences and Thermo Fisher Scientific with focus on utilization of molecular assays and next-generation sequencing (NGS) for diagnostics of rare disease and clinical oncology. Prior to that Dr. Vishnevetsky served and as Vice President of Sales and Marketing at WaferGen Biosystems and held sales management, marketing, and corporate strategy positions of increasing responsibility at Life Technologies-Invitrogen.  

Dr. Vishnevetsky obtained a postdoctoral appointment in biology from the California Institute of Technology and holds a Ph.D. degree in Molecular Biology from Hebrew University of Jerusalem. 

Discover how Fabric Genomics can help you
succeed with NGS testing